Limits...
No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis.

Shaw FL, Kimber I, Begum R, Cumberbatch M, Dearman RJ, Griffiths CE - Clin. Exp. Dermatol. (2011)

Bottom Line: The cytokine and chemokine content of supernatants was analysed by cytokine array.CD14+ cells acquired an LC-like phenotype with high expression of CD1a and major histocompatibility complex (MHC) class II.Moreover, mLCs isolated from both groups displayed comparable ability to migrate in vitro.

View Article: PubMed Central - PubMed

Affiliation: Toxicology Group, Faculty of Life Sciences, University of Manchester, Manchester, UK. frances.shaw@manchester.ac.uk

Show MeSH

Related in: MedlinePlus

CD1a, CD86, CD54 and major histocompatibility complex class II expression by unstimulated (med) and cytokine-stimulated [interleukin (IL)-1β and tumour necrosis factor (TNF)-α; both 100 ng/mL] monocyte-derived Langerhans cells derived from both (a) healthy controls and (b) patients with early-onset psoriasis. Each individual is represented by a single point on the graph, with the mean displayed as a horizontal bar. *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298657&req=5

fig02: CD1a, CD86, CD54 and major histocompatibility complex class II expression by unstimulated (med) and cytokine-stimulated [interleukin (IL)-1β and tumour necrosis factor (TNF)-α; both 100 ng/mL] monocyte-derived Langerhans cells derived from both (a) healthy controls and (b) patients with early-onset psoriasis. Each individual is represented by a single point on the graph, with the mean displayed as a horizontal bar. *P < 0.05.

Mentions: Baseline expression of surface markers as measured by flow cytometry was equivalent between mLCs derived from patients with psoriasis and from healthy controls (Figs 1,2). mLCs derived from patients with psoriasis were also able to respond to stimulation to the same extent as those derived from healthy volunteers, demonstrating that there was no impairment in their maturation ability (Figs 1, 2). For example, stimulation with IL-1β upregulated CD86 expression by approximately threefold in both the mLCs derived from patients and those derived from controls. CD54 expression was upregulated by both TNF-α and IL-1β to the same extent (approximately twofold) in both groups (P < 0.05; Fig. 2). Expression of MHC class II in both unstimulated and stimulated cells was equivalent between groups, and although there was a slight increase in this expression following stimulation, this was only significant for the patients following IL-1β stimulation (Fig. 2). There was a trend for CD1a intensity to be decreased in the mLCs derived from patients compared with those derived from healthy controls, but this was not significant (P > 0.05; Fig. 2).


No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis.

Shaw FL, Kimber I, Begum R, Cumberbatch M, Dearman RJ, Griffiths CE - Clin. Exp. Dermatol. (2011)

CD1a, CD86, CD54 and major histocompatibility complex class II expression by unstimulated (med) and cytokine-stimulated [interleukin (IL)-1β and tumour necrosis factor (TNF)-α; both 100 ng/mL] monocyte-derived Langerhans cells derived from both (a) healthy controls and (b) patients with early-onset psoriasis. Each individual is represented by a single point on the graph, with the mean displayed as a horizontal bar. *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298657&req=5

fig02: CD1a, CD86, CD54 and major histocompatibility complex class II expression by unstimulated (med) and cytokine-stimulated [interleukin (IL)-1β and tumour necrosis factor (TNF)-α; both 100 ng/mL] monocyte-derived Langerhans cells derived from both (a) healthy controls and (b) patients with early-onset psoriasis. Each individual is represented by a single point on the graph, with the mean displayed as a horizontal bar. *P < 0.05.
Mentions: Baseline expression of surface markers as measured by flow cytometry was equivalent between mLCs derived from patients with psoriasis and from healthy controls (Figs 1,2). mLCs derived from patients with psoriasis were also able to respond to stimulation to the same extent as those derived from healthy volunteers, demonstrating that there was no impairment in their maturation ability (Figs 1, 2). For example, stimulation with IL-1β upregulated CD86 expression by approximately threefold in both the mLCs derived from patients and those derived from controls. CD54 expression was upregulated by both TNF-α and IL-1β to the same extent (approximately twofold) in both groups (P < 0.05; Fig. 2). Expression of MHC class II in both unstimulated and stimulated cells was equivalent between groups, and although there was a slight increase in this expression following stimulation, this was only significant for the patients following IL-1β stimulation (Fig. 2). There was a trend for CD1a intensity to be decreased in the mLCs derived from patients compared with those derived from healthy controls, but this was not significant (P > 0.05; Fig. 2).

Bottom Line: The cytokine and chemokine content of supernatants was analysed by cytokine array.CD14+ cells acquired an LC-like phenotype with high expression of CD1a and major histocompatibility complex (MHC) class II.Moreover, mLCs isolated from both groups displayed comparable ability to migrate in vitro.

View Article: PubMed Central - PubMed

Affiliation: Toxicology Group, Faculty of Life Sciences, University of Manchester, Manchester, UK. frances.shaw@manchester.ac.uk

Show MeSH
Related in: MedlinePlus